Better therapies for a broad range of neurological diseases
Aleva Neurotherapeutics has raised €46M across 5 funding rounds from 2 investors, most recently a Series D+ round in Oct 2017. Based in Lausanne, Switzerland; founded 2008; active in Healthtech. Data as of 6 Aug 2026.
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2017-10-03 | Series D+ | €11M | Forrestal Capital | View deal → |
| 2016-05-01 | Series C | €16M | Banexi Ventures | View deal → |
| 2014-05-01 | Series B | €5.8M | — | View deal → |
| 2012-04-01 | Series B | €3.3M | Banexi Ventures | View deal → |
| 2011-08-01 | Series A | €9.5M | — | View deal → |
